Bavarian Nordic signs major deal for cancer vaccine

Bristol-Myers Squibb signs exclusive agreement with Bavarian Nordic for PROSTVAC, a prostate-specific antigen-targeting cancer immunotherapy.

Bavarian Nordic, headquartered in Greater Copenhagen, and Bristol-Myers Squibb Company announced on 4 March 2015 an agreement that provides Bristol-Myers Squibb an exclusive option to license and commercialise PROSTVAC, Bavarian Nordics investigational phase 3 prostate-specific antigen-targeting cancer immunotherapy in development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).

PROSTVAC is a ready to use immuno-oncology agent that stimulates an immune response that attacks prostate cancer cells. Administered subcutaneously, PROSTVAC employs Bavarian Nordics active immunotherapy (vaccinia-fowlpox/TRICOM) technology platform. When PSA-TRICOM is presented to the immune system in the PROSTVAC regimen, cytotoxic T lymphocytes (CTLs) are generated that may recognise and kill PSA-expressing cancer cells and trigger an immune response to other tumor antigens.

PROSTVAC is currently being evaluated in a global, randomised, double-blind, placebo-controlled phase 3 study (PROSPECT), that has fully enrolled at 1,298 patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).

Previous clinical studies of PROSTVAC, either as single-agent therapy or in combination with anti-androgen therapies, radiation therapies or immune checkpoint inhibitors have indicated possible therapeutic synergies for these treatment combinations and PROSTVAC has been generally well-tolerated.